Tilleman Quoted on Repealing the ACA and Potential Benefits for Health Care Executives
16 January 2017
Morgan Tilleman was quoted in a Managed Healthcare Executive article, “Six things to know: How health execs might benefit from Trump’s plans,” which focuses on President Trump’s plans to repeal the Affordable Care Act (ACA) and how this and other health care reforms could benefit managed health care executives.
When discussing limited medical underwriting for certain factors, including age and tobacco use, Tilleman said, “These underwriting restrictions make the young and healthy bear more than their fair share of the costs of individual health insurance and have contributed to huge premium increases.” He adds, “Under the ACA, insurers are unable to appropriately price health risk, which puts the entire individual market at risk of collapse. If Trump and Congress remove the ACA’s restrictions on underwriting, they will make a big contribution to restoring a healthy individual health insurance market.”
Tilleman also spoke to initiatives to improve the Medicaid program. “Insurers will have the opportunity to work with states in developing and implementing new Medicaid programs with block granted money; these programs could advance the use of medical homes and quality-driven healthcare that could pay dividends well beyond Medicaid in the future.”
When discussing limited medical underwriting for certain factors, including age and tobacco use, Tilleman said, “These underwriting restrictions make the young and healthy bear more than their fair share of the costs of individual health insurance and have contributed to huge premium increases.” He adds, “Under the ACA, insurers are unable to appropriately price health risk, which puts the entire individual market at risk of collapse. If Trump and Congress remove the ACA’s restrictions on underwriting, they will make a big contribution to restoring a healthy individual health insurance market.”
Tilleman also spoke to initiatives to improve the Medicaid program. “Insurers will have the opportunity to work with states in developing and implementing new Medicaid programs with block granted money; these programs could advance the use of medical homes and quality-driven healthcare that could pay dividends well beyond Medicaid in the future.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”